Biomunex Pharmaceuticals Overview

  • Founded
  • 2014

Founded
  • Status
  • Private

  • Employees
  • 8

Employees
  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $3.48M

  • Investors
  • 5

Biomunex Pharmaceuticals General Information

Description

Developer of immunotherapies designed to deliver therapeutics in the area of immuno-oncology. The company's immunotherapies offer to develop drug candidates with high anti-tumor potential, superior manufacturability, and optimal drug-like properties, enabling biotechnology companies to format antibodies from any pair of monospecific monoclonal antibodies as building blocks in a timely and cost-effective manner.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 14 avenue d'Eylau
  • 75116 Paris
  • France

Biomunex Pharmaceuticals Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biomunex Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Grant 03-Nov-2021 $3.48M 00.000 Completed Generating Revenue
5. Later Stage VC (Series A) 16-Feb-2021 00.000 00.000 000.00 Completed Generating Revenue
4. Seed Round Completed Startup
3. Accelerator/Incubator Completed Startup
2. Grant 01-Jan-2016 Completed Startup
1. Grant 01-Jan-2014 Completed Startup
To view Biomunex Pharmaceuticals’s complete valuation and funding history, request access »

Biomunex Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000,000 00.000000 000.0 000.0 00 000.0 00.00
To view Biomunex Pharmaceuticals’s complete cap table history, request access »

Biomunex Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of immunotherapies designed to deliver therapeutics in the area of immuno-oncology. The company's immunotherap
Drug Discovery
Paris, France
8 As of 2022
00.000
0000000000 00.000

00 000

derit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupida
0000000000000
Durham, NC
000 As of 0000
00000
000000 - 000 00000

000 00

it amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna ali
0000 000000000
Barcelona, Spain
00 As of 0000
0000
00000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Biomunex Pharmaceuticals Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
G1 Therapeutics Formerly VC-backed Durham, NC 000 00000 000000 - 000 00000
000 000000000000 Venture Capital-Backed Barcelona, Spain 00 0000 00000000000 0000
00000000 Venture Capital-Backed Boston, MA 00 0000 00000000000 0000
0000000 000000 Venture Capital-Backed Barcelona, Spain 00 0000 000000000000 0000
0000000-00000 0000 Corporation New York, NY 00000 00000 000000000 00000
You’re viewing 5 of 8 competitors. Get the full list »

Biomunex Pharmaceuticals Patents

Biomunex Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3565847-A1 A polypeptide linker for preparing multispecific antibodies Pending 09-Jan-2017 0000000000
CA-3052084-A1 A polypeptide linker for preparing multispecific antibodies Pending 09-Jan-2017 0000000000
JP-2020503873-A Polypeptide linkers for preparing multispecific antibodies Pending 09-Jan-2017 0000000000 00
AU-2018206229-A1 A polypeptide linker for preparing multispecific antibodies Pending 09-Jan-2017 0000000000
US-20190330377-A1 A polypeptide linker for preparing multispecific antibodies Pending 09-Jan-2017 C07K16/468
To view Biomunex Pharmaceuticals’s complete patent history, request access »

Biomunex Pharmaceuticals Executive Team (6)

Name Title Board Seat Contact Info
Pierre-Emmanuel Gerard MD Co-Founder & Chief Executive Officer
Stéphane Milot Chief Administrative Officer & Chief Financial Officer
Eugene Zhukovsky Ph.D Chief Technology Officer & Board Member
Simon Plyte Ph.D Chief Scientific Officer & Board Member
You’re viewing 4 of 6 executive team members. Get the full list »

Biomunex Pharmaceuticals Board Members (8)

Name Representing Role Since
Alain Dublin Self Board Member 000 0000
C. Grace Yeh Onward Therapeutics Board Member 000 0000
Dragan Grabulovski Ph.D Self Board Observer 000 0000
Eugene Zhukovsky Ph.D Biomunex Pharmaceuticals Chief Technology Officer & Board Member 000 0000
Jordi Esclusa Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Biomunex Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biomunex Pharmaceuticals Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
French Government Government Minority 000 0000 000000 0
Onward Therapeutics Corporation Minority 000 0000 000000 0
L'Agence Nationale de la Recherche Government 000 0000 000000 0
Bpifrance Sovereign Wealth Fund 000 0000 000000 0
Agoranov Accelerator/Incubator Minority 000 0000 000000 0
To view Biomunex Pharmaceuticals’s complete investors history, request access »